-
Optimizing Profitability in Drug Product Manufacturing with Hard-Shell Capsules
Hard-shell capsules are more simple to formulate and easier to produce than other types of solid dose.
PAP-Q3-18-CL-003 -
Patient Centricity and the Pharmaceutical Supply Chain: An Evolving Dynamic
Becoming a true patient-centric industry requires significant effort and a complete change in the way pharmaceutical companies operate.
PAP-Q3-18-NI-004 -
Dedicated CDMO Services Meet Customer Needs in the Dynamic Biopharma Sector
Biologic drug substances are increasingly complex, and as such their sophisticated biomanufacturing is exceedingly challenging.
PAP-Q3-18-CL-004 -
Aspects to Consider on the Way to a Tailored Manufacturing Strategy
Often, the best decision for a company’s bottom line is to rely on an experienced manufacturing partner.
PAP-Q3-18-CL-005 -
People, Expertise and Dedication are Key to Successful Strategic Partnerships
Strategic partnerships are all about dedicating people to work togethe, so that all available expertise is accessible for a project’s success.
PAP-Q3-18-CL-006 -
Leveraging Offsite Fabrication in the Pharma Industry
Leveraging offsite fabrication offers a range of benefits, including improved safety, schedule predictability and reduced costs.
PAP-Q3-18-CL-007 -
Analytical Methodologies Utilized in Therapeutic Viral Vector Manufacturing
Given the range of impurities that can be present in viral vector drug substance/drug product, diverse analytical techniques are needed.
PAP-Q3-18-CL-001 -
Understanding the Unique Design and Engineering Needs for Gene Therapy Production
Designing gene therapy manufacturing facilities requires applying existing technologies and systems in new ways.
PAP-Q3-18-CL-008 -
A Biopharmaceutical Leader Emerges
For Polpharma Biologics, the new website reflects the vision to become a trusted source of biopharmaceutical products and services.
PAP-Q3-18-NI-002 -
A Vision for Growth Tailored to Our Partners’ Needs
We constantly seek opportunities for improvement –– in how we deliver our products, process orders, develop new products and communicate with our partners.
PAP-Q3-18-CL-009 -
Accelerating Time to Market with Integrated Preparative Chromatography Support
While preparative chromatography can enable difficult separations, it requires specialized equipment and expertise.
PAP-Q3-18-CL-010 -
Creating Value with Tailored ODT Solutions
One approach is to use a commercially available orally dispersible drug delivery platform to facilitate development and speed to market.
PAP-Q3-18-CL-011 -
Pursuing Patient Centricity from Start to Finish
Patient centricity must be integrated into every area and aspect of the supply chain.
PAP-Q3-18-NI-005 -
Remember the User – Incorporating Patient Centricity into Drug Design
Developers must consider what works for patients and how this design will be adopted in a real-world context.
PAP-Q3-18-NI-006 -
The Impact of Patients as Consumers: New Fill/Finish and Packaging Solutions
Poor medication adherence continues to be a huge issue for the pharmaceutical industry.
PAP-Q3-18-NI-007 -
Personalized Logistics Solutions for Virtual and Hybrid Clinical Trials
The key to a successful hybrid trial is understanding which aspects will include patient home care and DTP/DFP trial components.
PAP-Q3-18-CL-002 -
New Look, Same Unwavering Patient Commitment
Marken is both a service and technology provider, so user experience and functionality were key considerations in redesigning its website.
PAP-Q3-18-NI-001 -
Competitive Generic Therapy: A New Patient-Centric FDA Pathway
The CGT pathway was designed to incentivize the development of generics for drugs for which there is effectively no market competition.
PAP-Q3-18-NI-008 -
Increasing Customer Successes Through Enhanced QC Agility and Flexibility
The development of increasingly complex drug substances requires associated advances in testing.
PAP-Q3-18-CL-012 -
Continuing on the Acquisition Trail: Building Out a World-Class, Customer-Oriented CDMO
At the core of each acquisition decision is the potential to improve the customer experience.
PAP-Q3-18-CL-013 -
Aligning with Sponsors for Strategic Growth
Alcami’s ultimate goal is to become an industry-leading CDMO focused on small and mid-sized pharma customers.
PAP-Q3-18-CL-014 -
Terminal Sterilization for Parenteral Drugs: Finding the Right CDMO Partner
Selecting an appropriate sterilization method requires an understanding of the drug substance and the final formulated product.
PAP-Q3-18-CL-015 -
Meeting Regulatory Requirements: Rising to the Challenge with a Trusted Equipment Partner
In order for a company to fully prepare for and conform to all DSCA measures, updated equipment is a must.
PAP-Q3-18-CL-016 -
The Biotech Boom
Regardless of whether a biotech company has demonstrated results, it is perceived to have intrinsic value.
PAP-Q3-18-NI-003
-
Increasing Customer Successes Through Enhanced QC Agility and Flexibility
Daniel Dixon, Vice President of Quality Control, UPM Pharmaceuticals, explains the importance of QC in CDMOs.
-
Product and Service Concepts Driving Speed to Market
Jonathan Gilinski, Executive Director of CapsCanada explains how to accelerate timelines.
-
Analytical Methodologies Utilized in Therapeutic Viral Vector Manufacturing
Richard Snyder, Sushma Ogram, and Tony DeFusco of Brammer Bio highlight the analytical techniques involved in viral vector production.
-
Meeting Regulatory Requirements: Rising to the Challenge with a Trusted Equipment Partner
Equipment upgrades are key to new regulatory requirements, according to Adam Covitt, Vice President of Federal Equipment Company.
-
Flexible Partnership, Inflexible Quality
Driven by the demand for biologics, most of which still require parenteral administration, the sterile injectable market is projected to continue its 6% annual growth through 2020.
-
Aligning with Sponsors for Strategic Growth
Syed T. Husain, Chief Commercial Officer, and Catherine Hanley, Head of Marketing & Corporate Communications, Alcami, discuss the new company sponsorship.
-
FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing
The ID CORE XT kit will benefit patients who require ongoing transfusions including individuals with hemoglobinopathies such as sickle-cell disease (SCD) and thalassemia.
-
GSK Funds British Biotech Sitryx
Immunometabolism start-up completes $30 million funding round.
-
New Diabetes Drug Shows Promise in Phase 2 Study
Eli Lilly and Company's dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA) LY3298176 led to lowered blood sugar levels and weight loss.
-
Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma
STRO-001 is a potential first-in-class antibody drug conjugate (ADC) targeting CD74, a protein highly expressed in B-cell malignancies such as multiple myeloma.
-
Continuing on the Acquisition Trail: Building Out a World-Class, Customer-Oriented CDMO
Tim Tyson, Chairman and CEO of Avara Pharmaceutical Services, discusses the company's acquisition strategy.
-
Dedicated CDMO Services Meet Customer Needs in the Dynamic Biopharma Sector
Federico Pollano, Senior Vice President Business Development, Rentschler Biopharma SE, outlines the advantages of a dedicated CDMO.
-
Understanding the Unique Design and Engineering Needs for Gene Therapy Production
Designing gene therapy manufacturing facilities presents unique challenges, says Peter Walters, Lead Process Engineer, CRB USA.
-
Aspects to Consider on the Way to a Tailored Manufacturing Strategy
David Brett, Team Leader Product and Service Management at Vetter Pharma International GmbH, discusses strategies in outsourced manufacturing.
-
FDA Approves Expanded Use of Gardasil 9 to Include Individuals 27 Through 45 years old
Gardasil 9 prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine.
-
Global Pediatric Vaccine Market 2015-2024: Technologic Advancements and Increase in Government and Non-Government Funding
Global pediatric vaccine market is expected to grow with a CAGR of around 12.6% over the forecast period 2017-2024.
-
New Clinical Trial Will Evaluate Biomarkers as Predictors of Treatment Response in IBD
Allergan is evaluating the use of biomarkers for the prediction of response to its IL-23 candidate brazikumab in patients with inflammatory bowel disease (IBD).
-
U.S. Department of Veterans Affairs Signs Contract with Merck for its Remicade Biosimilar
National contract was won due to its attractive pricing offer.
-
Personalized Logistics Solutions for Virtual and Hybrid Clinical Trials
Ariette van Strien, Chief Commercial Officer, Marken, discusses siteless/hybrid clinical trials.
-
Leveraging Offsite Fabrication in the Pharma Industry
Offsite fabrication of facility components and equipment can help drug manufacturers achieve their goals, says Dennis Kearney, Pharmaceutical Core Team Leader at CRB USA.
Nice Insight Awareness/Perception Scorecard
Research. Compare. Contact. Find the Ideal Partner.
Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.
- Search by company type, region, market segment and services.
- Select up to 5 companies to compare.
- View CA & CP performance scores against industry benchmark ratings.
Latest
View All LatestFDA Gives De Novo Clearance to First Over-the-Counter Hearing Aid
Oct 16, 2018 11:59:49 AM PAO-M10-18-NI-015New Collaboration Aimed at Improving Cancer Diagnostics in the UK
Oct 16, 2018 11:57:19 AM PAO-M10-18-NI-014UK Hospital to Get Command Center Driven by AI and Real-Time Analytics
Oct 16, 2018 11:53:40 AM PAO-M10-18-NI-013U.S. Department of Veterans Affairs Signs Contract with Merck for its Remicade Biosimilar
Oct 12, 2018 2:33:02 PM PAO-M10-18-NI-010New Clinical Trial Will Evaluate Biomarkers as Predictors of Treatment Response in IBD
Oct 12, 2018 2:22:42 PM PAO-M10-18-NI-009Another PD-1/L1 Drug Gets Priority Approval from the US FDA
Oct 4, 2018 10:56:10 AM PAO-M10-18-NI-004
TOPICS
View All TopicsPRESS RELEASES
View All-
GHIT Fund Welcomes Ono Pharmaceutical Co., Ltd. as New Funding Partner
Oct 17, 2018 5:00:00 AM -
New Study Examines How Pharmaceutical Industry is Embracing Digital Patient Engagement Programs
Oct 17, 2018 5:00:00 AM -
Microsoft Genomics Ventures into the Microbiome With Eagle Genomics
Oct 16, 2018 5:00:00 AM
Nice Insight Industry Benchmark Reports 2017
Download Sample Report
